

**FORM 51-102F3**  
**MATERIAL CHANGE REPORT**

**Item 1. Name and Address of Company**

Friday Night Inc., formerly QuikFlo Health Inc. ("FNI" or the "Company")  
734 – 1055 Dunsmuir Street  
Vancouver, BC  
V7X 1B1

**Item 2. Date of Material Change**

October 4, 2017

**Item 3. Report**

On October 5, 2017, a press release relating to the material change was issued and disseminated through the services of FSC Wire.

**Item 4. Summary Of Material Change**

The Company announced that it has closed its previously announced non-brokered private placement of \$1,000,000 aggregate principal amount of convertible debenture units at a price of \$1,000 per Convertible Debenture Unit. Each Convertible Debenture Unit consists of a \$1,000 principal amount 10% senior unsecured convertible debenture and 4,000 common share purchase warrants. Each Warrant is exercisable to acquire one common share of the Company at an exercise price of \$0.25 per Warrant Share until October 4, 2019.

The Convertible Debentures bear interest from the date of closing at 10.0% per annum (subject to withholdings for non-residents), semi-annually on June 30 and December 31 of each year and will expire on August 16, 2019. The Debentures are convertible into Common Shares at the option of the holder at any time prior to the close of business on the earlier of: (i) the last business day immediately preceding the Maturity Date; and (ii) the date fixed for redemption, at a conversion price of \$0.25 per Common Share, subject to adjustment in certain events.

**Item 5. Full Description Of Material Change**

The Company has closed its previously announced (October 2, 2017) private placement of \$1,000,000 aggregate principal amount of convertible debenture units at a price of \$1,000 per Convertible Debenture Unit. Each Convertible Debenture Unit consists of a \$1,000 principal amount 10% senior unsecured convertible debenture and 4,000 common share purchase warrants of the Company. Each Warrant is exercisable to acquire one common share of the Company at an exercise price of \$0.25 per Warrant Share until October 4, 2019, provided that if, at any time after February 5, 2018 and prior to the expiry date of the Warrants, the volume weighted average trading price of the common shares of the Company equals or exceeds \$0.50 for 10 consecutive trading days, the Company may, within 30 days of the occurrence of such event, deliver a notice to the holders of the Warrants accelerating the expiry date of the Warrants to the date that is 30 days following the date of such notice. Any unexercised Warrants shall automatically expire at the end of the accelerated exercise period.

The Convertible Debentures bear interest from the date of closing at 10.0% per annum (subject to withholdings for non-residents), semi-annually on June 30 and December 31 of each year and will expire on August 16, 2019. The Debentures are convertible into Common Shares at the option of the holder at any time prior to the close of business on the earlier of: (i) the last business day immediately preceding the Maturity Date; and (ii) the date fixed for redemption, at a conversion price of \$0.25 per Common Share, subject to adjustment in certain events. Additionally, beginning on February 5, 2018, the Company may force the conversion of all of the principal amount of the then outstanding Convertible Debentures at the Conversion Price on 30 days prior written notice should the daily volume weighted average trading price of the Common Shares be greater than \$0.45 for any 10 consecutive trading days. The Convertible Debentures will be subject to redemption, in whole or in part, by the Company at any time after October

4, 2018 upon giving holders not less than 30 and not more than 60 days' prior written notice, at a price equal to the then outstanding principal amount of the Convertible Debentures plus all accrued and unpaid interest up to and including the redemption date.

The Company paid finder's fees of \$6,000 and issued 24,000 warrants to certain arm's-length parties in the connection with the Offering.

The Company intends to use the net proceeds of the Offering for expanding its growing operations in Las Vegas, Nevada and for general corporate purposes.

**Item 6. Reliance on subsection 7.1(2) of National Instrument 51-102**

Not applicable.

**Item 7. Omitted Information**

No information has been omitted on the basis that it is confidential information.

**Item 8. Executive Officer**

Brayden Sutton, 604-428-0511.

**Item 9. Date of Report**

October 6, 2017.